Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Cefepime monotherapy for febrile neutropenia in patients with lung cancer.

Saito H, Takahashi K, Okuno M, Saka H, Imaizumi K, Hasegawa Y, Tanikawa Y, Yamamoto M, Taniguchi H, Shindoh J, Suzuki R, Shimokata K; Central Japan Lung Study Group.

J Infect Chemother. 2014 Jun;20(6):365-9. doi: 10.1016/j.jiac.2014.02.002. Epub 2014 Mar 26.

PMID:
24679653
2.

Clinical efficacy and safety of cefepime in febrile neutropenic patients with lung cancer.

Fujita M, Ouchi H, Inoue Y, Inoshima I, Ohshima T, Yoshimura C, Wataya H, Kawasaki M, Tokunaga S, Nakanishi Y; Lung Oncology Group in Kyushu (LOGIK).

J Infect Chemother. 2010 Apr;16(2):113-7. doi: 10.1007/s10156-010-0030-3. Epub 2010 Feb 4.

PMID:
20130951
3.

Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia.

Montalar J, Segura A, Bosch C, Galan A, Juan O, Molins C, Giner V, Aparicio J.

Med Oncol. 2002;19(3):161-6.

PMID:
12482126
4.

The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study.

Fujita M, Matsumoto T, Inoue Y, Wataya H, Takayama K, Ishida M, Ebi N, Kishimoto J, Ichinose Y; Lung Oncology Group in Kyushu (LOGIK).

J Infect Chemother. 2016 Apr;22(4):235-9. doi: 10.1016/j.jiac.2016.01.005. Epub 2016 Feb 8.

PMID:
26867793
5.
6.

[Cefepime as an empiric treatment of febrile neutropenia in patients after high dose therapy and autologous stem cell transplantation].

Zikesoá E, Hnátková M, Vacková B, Jedlicková A, Klener P, Trnený M.

Cas Lek Cesk. 2006;145(5):383-6, 388-9. Czech.

PMID:
16755776
7.

Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer.

Chuang YY, Hung IJ, Yang CP, Jaing TH, Lin TY, Huang YC.

Pediatr Infect Dis J. 2002 Mar;21(3):203-9.

PMID:
12005083
8.

Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia.

Mustafa MM, Carlson L, Tkaczewski I, McCracken GH Jr, Buchanan GR.

Pediatr Infect Dis J. 2001 Mar;20(3):362-9. Review.

PMID:
11303851
9.

Elevation of serum C-reactive protein predicts failure of the initial antimicrobial treatment for febrile neutropenia with lung cancer.

Matsumoto T, Fujita M, Hirota T, Takeda S, Hirano R, Uchino J, Harada T, Watanabe K.

J Infect Chemother. 2013 Apr;19(2):202-7. doi: 10.1007/s10156-012-0474-8. Epub 2012 Sep 28.

PMID:
23053498
10.

Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial.

Kwon KT, Cheong HS, Rhee JY, Wi YM, Ryu SY, Heo ST, Moon CS, Ki HK, Kim KH, Jung CW, Peck KR, Song JH.

Jpn J Clin Oncol. 2008 Jan;38(1):49-55. doi: 10.1093/jjco/hym151. Epub 2008 Jan 17.

PMID:
18203711
11.

Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.

Nakane T, Tamura K, Hino M, Tamaki T, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A; Japan Febrile Neutropenia Study Group.

J Infect Chemother. 2015 Jan;21(1):16-22. doi: 10.1016/j.jiac.2014.08.026. Epub 2014 Sep 17.

PMID:
25239059
12.

Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.

Jimeno A, Arcediano A, Bazares S, Amador ML, González-Cortijo L, Ciruelos E, Robles L, Castellano D, Paz-Ares L, Lumbreras C, Hornedo J, Cortés-Funes H.

Clin Transl Oncol. 2006 Dec;8(12):889-95.

PMID:
17169762
13.

A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.

Bow EJ, Rotstein C, Noskin GA, Laverdiere M, Schwarer AP, Segal BH, Seymour JF, Szer J, Sanche S.

Clin Infect Dis. 2006 Aug 15;43(4):447-59. Epub 2006 Jul 10.

PMID:
16838234
14.

Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.

Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D.

Am J Med. 1996 Jun 24;100(6A):83S-89S.

PMID:
8678102
15.

Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).

Biron P, Fuhrmann C, Cure H, Viens P, Lefebvre D, Thyss A, Viot M, Soler-Michel P, Rollin C, Grès JJ.

J Antimicrob Chemother. 1998 Oct;42(4):511-8.

PMID:
9818751
16.

Prospective study of empiric monotherapy with ceftazidime for low-risk grade IV febrile neutropenia after cytotoxic chemotherapy in cancer patients.

Chernobelski P, Lavrenkov K, Rimar D, Riesenberg K, Schlaeffer F, Ariad S, Mermershtain W.

Chemotherapy. 2006;52(4):185-9. Epub 2006 May 2.

PMID:
16675902
17.

Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia.

Bucaneve G, Micozzi A, Picardi M, Ballanti S, Cascavilla N, Salutari P, Specchia G, Fanci R, Luppi M, Cudillo L, Cantaffa R, Milone G, Bocchia M, Martinelli G, Offidani M, Chierichini A, Fabbiano F, Quarta G, Primon V, Martino B, Manna A, Zuffa E, Ferrari A, Gentile G, Foà R, Del Favero A.

J Clin Oncol. 2014 May 10;32(14):1463-71. doi: 10.1200/JCO.2013.51.6963. Epub 2014 Apr 14.

PMID:
24733807
18.

Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.

Raad II, Escalante C, Hachem RY, Hanna HA, Husni R, Afif C, Boktour MR, Whimbey EE, Kontoyiannis D, Jacobson K, Kantarjian H, Levett LM, Rolston KV.

Cancer. 2003 Sep 1;98(5):1039-47.

19.

Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.

Pereira CA, Petrilli AS, Carlesse FA, Luisi FA, da Silva KV, de Martino Lee ML.

J Microbiol Immunol Infect. 2009 Apr;42(2):141-7.

PMID:
19597646
20.

Treatment of febrile neutropenia with cefepime monotherapy.

Jándula BM, Martino R, Gurgi M, Manteiga R, Sierra J.

Chemotherapy. 2001 May-Jun;47(3):226-31.

PMID:
11306793

Supplemental Content

Support Center